Study of Lonidamine in Lung Cancer
Author Information
Author(s): O. Kokron, S. Maca, M. De Gregorio, G.B. Ciottoli
Primary Institution: Ludwig Boltzmann Institut fur Klinische Onkologie, Vienna, Austria
Hypothesis
Does lonidamine have anti-tumor activity in patients with non-small cell lung cancer?
Conclusion
Lonidamine showed some anti-tumor activity in non-small cell lung cancer, particularly in earlier stages and epidermoid carcinomas.
Supporting Evidence
- Partial responses occurred in 10.1% of patients.
- The median survival for the whole group was 261 days.
- No myelosuppression was observed in patients.
Takeaway
This study tested a new cancer drug called lonidamine on patients with lung cancer, and it helped some of them feel better.
Methodology
Patients with non-small cell lung cancer were treated with lonidamine and monitored for response and side effects over several years.
Limitations
The study had a small sample size and was limited to patients with inoperable cancer.
Participant Demographics
54 male and 15 female patients with a median age of 62 years.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.02
Want to read the original?
Access the complete publication on the publisher's website